Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (23 ops.)
Latest filing published 02 Jun 2025 for Kyverna Therapeutics, Inc.. Read the official filing
Filing timeline
BuySaleDaniel K. Spiegelman
Insider track record
Disclosed buys
0
Disclosed sells
23
Signal history
Daniel K. Spiegelman: trading record in brief
Daniel K. Spiegelman, listed as board member, has filed trades across 5 companies (mainly through SEC (Form 4)), most often in Biomarin Pharmaceutical Inc, Myriad Genetics Inc and Cascadian Therapeutics, Inc. In total, 77 filings cover trades dated from 27 May 2015 to 29 May 2025.
Sales make up the whole of the open-market record (23 sales, €15.3M). Besides market trades, the filings include 44 share grants and 6 option exercises.
The latest filing, published on 2 June 2025, reports a share grant in Kyverna Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Daniel K. Spiegelman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations9 total
16,634 shares0Common StockSEC:0000950170-25-080456:0
3,788 shares@ US$22.0417.3% of flowCommon StockSEC:0001238403-24-000002:0
15,151 shares0Common StockSEC:0001238403-23-000002:0
6,424 shares@ US$19.251726.1% of flowCommon StockSEC:0001238403-22-000002:0
17,275 shares0Common StockSEC:0001628280-22-016223:0
3,139 shares@ US$30.517618.2% of flowCommon StockSEC:0001238403-21-000008:0
12,848 shares0Common StockSEC:0001238403-21-000006:0
7,142 shares@ US$28.986738.4% of flowCommon StockSEC:0001238403-21-000004:0
15,889 shares0Common StockSEC:0001238403-21-000002:0
9 of 9 declarations
